Results 11 to 20 of about 459,727 (225)
Meningococcal conjugate vaccines: optimizing global impact
Infection and Drug Resistance, 2011 Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj +1 more source
Meningococcal Vaccination:: An Update on Meningococcal Vaccine Recommendations for the Primary Care Physician. [PDF]
Dela J Public Health, 2022 Neisseria meningitidis is an aerobic, gram-negative, diplococcus bacterium that is a leading cause of meningitis and sepsis in the United States. Particularly at-risk groups include those with complement deficiencies, people using complement inhibitors, individuals with anatomic or functional asplenia, patients with HIV infection and travelers to ...
Nichols J, Eppes S.
europepmc +3 more sources
Therapeutics and Clinical Risk Management, 2008 Sanford R KimmelUniversity of Toledo College of Medicine, Department of Family Medicine, Toledo, OH, USAAbstract: Invasive meningococcal disease occurs worldwide causing an estimated 50,000–135,000 deaths each year in addition to significant ...
Sanford R Kimmel
doaj +1 more source
Bacterial outer membrane vesicles and vaccine applications [PDF]
, 2014 Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self ...
Jose Luis Perez +30 more
core +4 more sources
Meningococcal vaccines in China [PDF]
Human Vaccines & Immunotherapeutics, 2021 Meningococcal meningitis caused by Neisseria meningitidis is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s.
Yinghua Xu +5 more
openaire +3 more sources
Expert Review of Vaccines, 2002 The successful introduction of a protein-polysaccharide conjugate vaccine against serogroup C meningococci into the UK infant immunization schedule, in combination with a catch-up campaign for individuals less than 18 years of age, has seen virtually all group C disease eliminated in childhood.
Bethell, D, Pollard, A
openaire +4 more sources
Meningococcal Vaccinations [PDF]
Infectious Diseases and Therapy, 2016 Neisseria meningitidis, a gram-negative diplococcal bacterium, is a common asymptomatic nasopharyngeal colonizer that may infrequently lead to invasive disease in the form of meningitis or bacteremia. Six serogroups (A, B, C, W, X and Y) are responsible for the majority of invasive infections.
Crum-Cianflone, Nancy, Sullivan, Eva
openaire +2 more sources
Pediatric Infectious Disease Journal, 2004 The 5 major pathogenic serogroups of the Gram-negative encapsulated bacterium Neisseria meningitidis are A, B, C, Y, and W135. In the 1960s, vaccines consisting of purified capsular polysaccharide antigens were developed against serogroups A, C, Y, and W135.
Rüggeberg, J, Pollard, A
openaire +6 more sources
Meningococcal disease in children in Merseyside, England : a 31 year descriptive study [PDF]
, 2011 Meningococcal disease (MCD) is the leading infectious cause of death in early childhood in the United Kingdom, making it a public health priority. MCD most commonly presents as meningococcal meningitis (MM), septicaemia (MS), or as a combination of the ...
Hart, C. Anthony +12 more
core +3 more sources
Human Vaccines & Immunotherapeutics, 2012 Meningococcal meningitis is caused by Neisseria meningitidis, a gram-negative, aerobic, encapsulated diplococcus. Meningococci are divided into numerous serogroups based on the composition of their capsular polysaccharide (Ps) antigens. At least 13 serogroups have been described: A, B, C, D, 29E, H, I, K, L, W-135, X, Y and Z.
Ramesh, Verma, Pardeep, Khanna
openaire +2 more sources